Format

Send to

Choose Destination
  • Showing results for wayne brasky. Your search for Wayne Bresky retrieved no results.
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1345-1348. doi: 10.1158/1055-9965.EPI-17-0096.

Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative.

Author information

1
Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, Ohio. Theodore.Brasky@osumc.edu.
2
Division of Cancer Prevention and Control, The Ohio State University College of Medicine, Columbus, Ohio.
3
Division of Medical Dietetics and Health Sciences, The Ohio State University College of Medicine, Columbus, Ohio.
4
WHI Clinical Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, Washington.
5
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California.
6
Department of Epidemiology and Environmental Health, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York.
7
Memorial Healthcare System, Hollywood, Florida.
8
HealthPartners Institute, Minneapolis, Minnesota.
9
Division of Biostatistics, Department of Public Health Sciences, School of Medicine, University of California-Davis, Davis, California.
10
Department of Biobehavioral Nursing and Health Informatics, School of Nursing, University of Washington, Seattle, Washington.
11
Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
12
Stanford University School of Medicine, Stanford University, Stanford, California.
13
Departments of Preventive Medicine and Internal Medicine, University of Tennessee Health Science Center, Memphis, Tennessee.
14
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Abstract

Background: Use of calcium channel blockers (CCBs) has been associated with increased risk of breast cancer in some, but not all, studies. Differences in reported associations from prior studies may be due, in part, to inadequate control of confounding factors.Methods: Participants were 28,561 postmenopausal women from the Women's Health Initiative who reported use of either CCBs or other antihypertensive medications (AHMs) at baseline; 1,402 incident breast cancer cases were diagnosed during 12 years of follow-up. Adjusted Cox regression models were used to estimate HRs and 95% confidence intervals (CI) for the associations between CCB use relative to other AHM use and breast cancer risk.Results: Use of CCBs was not associated with breast cancer risk (HR, 1.06; 95% CI, 0.94-1.20) relative to use of other AHMs. Associations approximated the null value when CCBs were considered by duration of use, length of action, or drug class.Conclusions: We provide additional evidence that CCBs do not influence breast cancer risk in postmenopausal women.Impact: The results from this study, which includes strong control for potential confounding factors, cast doubt on increases in risk with CCBs. Cancer Epidemiol Biomarkers Prev; 26(8); 1345-8. ©2017 AACR.

PMID:
28765339
PMCID:
PMC5607775
DOI:
10.1158/1055-9965.EPI-17-0096
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center